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Median Pre
CD34 /uL
Median CD34/ kg
Initial Collection
Median CD34/ kg
Second Collection
Median % of
Initial Collection
Days to ANC
>0.5 x109/L
Days to Plt
>50 x109/L
NHL (n¼7) 2.1 (1.5-6.2) 1.5 (1.27-1.68) 0.68 (0.27-1.96) 41% (21-114) 11 (10-12) 16 (11->28)
MM (n¼3) 3.1 (3.1-5.7) 3.01 (1.85-3.77) 1.51 (1.11-3.01) 60% (40-85) 11 (9-12) 14 (13-14)
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high cost of P and the inability to determine which patients
will collect poorly using clinical parameters alone.
Previous studies have shown that the high cost of P is
justiﬁed based on fewer apheresis days required. However
when patients require 2 or more days of P the costs can
become prohibitive.
To alleviate the need for additional days of P we piloted an
approach where patients who were close to achieving their
target collection goal after the ﬁrst day of P continued their G
CSF, but without an additional dose of P. Minimum accepted
collection goals were 2 x 106 CD34/kg for NHL patients and 4
x 106CD34/kg for MM patients.
From April 2012 through April 2014 170 patients underwent
an autologous transplant. Fifty (29.4%) ultimately required P
to mobilize adequate numbers of cells. Ten patients (7 NHL, 3
MM) were judged close to their preset target collection goal
after their ﬁrst dose of P. These patients were collected the
following day without an additional dose of P.
As shown in Table 1 the median peripheral blood CD34/uL
count prior to collection was 2.1 for NHL and 3.1 for MM. The
median CD34 x 106/kg collected the day following the dose of
P was 1.5 (NHL) and 3.01 (MM). On the second day of
collection without P, the median CD34 x 106collected was
0.68 (NHL) and 1.51 (MM). All patients achieved their target
goals and were able to successfully proceed to trans-
plantation. The median percentage of the original collection
is 40 and 60% respectively for NHL and MM. All patients
engrafted with similar times to patients not requiring P, or
who had a successful collection with a single apheresis.
It appears that in patients who are close to achieving their
target dose, that the strategy of omitting the second dose of P
can successfully allow collection of sufﬁcient cells to permit
autologous transplant with appropriate engraftment times.
In our population 20% of the patients who received P fell into
this category.With a cost of approximately $7000 per patient
dose, the cost savings per 100 patients transplanted would
be approximately $42,000. Such an approach clearly
can minimize the costs associated with stem cell
mobilization and collection without any difference in the
clinical outcome.363
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Ambisome (amphotericin B liposomal complex, L-Amb) is
highly effective for the treatment of invasive fungal
infections (IFI) and may be an important prophylactic drug in
patients undergoing hematopoietic stem cell transplant(HSCT). Several new anti-fungal drugs have become available
over the past few years leading to various prospective studies
aiming to assess the role of prophylaxis and treatment in IFI
in HSCT. But drug related factors such as safety, efﬁcacy,
toxicity proﬁle in the setting of pre-existing organ dysfunc-
tion and potential drug interaction, need to be considered.
Ambisome is a liposomal formulation containing ampho-
tericin B and is comparatively found to cause fewer infu-
sional reactions and achieve superior plasma and tissue
concentrations.
To determine the optimal approach for prophylactic
antifungal therapy, we prospectively analyzed the efﬁcacy
and safety of low dose Ambisome, which is 1mg per kg
body weight on alternate days in nineteen patients who
underwent hematopoietic stem cell transplant at our insti-
tute, for the prophylaxis of IFI. This was a heterogeneous
study group, having varied indications for transplant.
Results: The low dose regimen of 1mg/kg body weight on
alternate days was well tolerated. Four out of nineteen
patients developed manageable hypokalemia. No renal
toxicity or infusional reactions were documented. However,
a test dosewas always administered. Only one patient having
a T replete haploidentical transplant for follicular lymphoma
developed probable IFI requiring anti-fungal therapy.
Conclusion: We conclude that low dose L-Amb may provide
useful protection against invasive fungal infections in
patients undergoing hematopoietic stem cell transplant.364
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Respiratory and skeletal muscle strength and submaximal
exercise capacity and physical activity levels are known to be
reduced in a signiﬁcant percentage of patients prior to
hematopoietic stem cell transplantation (HSCT). However,
determinants of physical activity levels of HSCT recipients
have not been investigated so far. The aim of this study was
to determine the role of physical activity levels in HSCT
recipients.
Patients and Methods: This prospective cross sectional
study included 36 HSCT recipients. Physical activity levels
were assessed using a multisensory armband device and
pulmonary function tests. Functional exercise capacity was
evaluated with 6-minute walking test (6MWT), respiratory
muscle strength (MIP, MEP) with mouth pressure device,
peripheral muscles strength with dynamometer, and
dyspnea with Modiﬁed Medical Research Council
(MMRC) dyspnea scale. Correlations of exercise capacity
parameters were done with the grade of cardiac and
pulmonary toxicity, febrile neutropenia, and transplant
related mortality (TRM).
Results: All HSCT recipients were inactive (<3.0 METs)
according to daily average METs (1.260.18 METs) and
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S25988.88% were walking <7.500 steps/day. Daily average METS
were inversely correlated withMMRC dyspnea scale (r 0.492,
p¼0.007). Adjusted DLCO values showed negative correla-
tion with the grade of febrile neutropenia (r 0.612, p¼0.007).
The grade of cardiac toxicity showed negative correlation
with adjusted DLCO values (p¼0.006) and quadriceps
femoris muscle strength (p¼0.046). Respiratory and
quadriceps femoris muscle strength were positively
correlated with the number of steps per day (p¼0.011 and
p¼0.001 respectively). Performance status prior to HSCT
showed negative correlation with TRM (p¼0.05). In multiple
regression analysis; 24% of the variance in the daily average
METs was explained by MMRC (p¼0.07); 13% of the variance
in survival duration explained by quadriceps femoris
strength (p¼0.03); 54.6 % of the variance in cardiac toxicity
was explained by DLCO and quadriceps femoris strength
(p¼0.024).
Conclusions: Physical inactivity is a signiﬁcant problem in
HSCT recipients. Peripheral muscle strength and dyspnea are
signiﬁcant predictors of physical activity levels. Exercise
interventions to improve cardiorespiratory ﬁtness and
muscle strength may lead to beneﬁcial effects on transplant
outcomes in terms of the grade of cardiorespiratory
toxicities, febrile neutropenia and TRM.365
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Tuberculosis is caused by the pathogenic species of the
Mycobacterium tuberculosis complex. Following a primary
tuberculosis infection, adequate T-lymphocyte responses are
essential to preventing the progression of disease. Patients
with hematologic malignancies are at increased risk for
reactivation of latent tuberculosis infection (LTBI) due to
T-cell immunodeﬁciency caused by the disease itself or the
chemotherapy used as treatment. Incidence of tuberculosis
varies signiﬁcantly depending on country of birth and
underlying hematologic malignancy. The highest rate has
been identiﬁed among allogeneic hematopoietic stem cell
transplant (HSCT) patients, followed by patients with
non-Hodgkin lymphoma and patients with Hodgkin’s
lymphoma. Isoniazid (INH) therapy may be initiated in
patients found to have LTBI. INH therapy carries the risk of
adverse effects including hepatotoxicity and peripheral
neuropathy. INH induced hepatotoxicity occurs in 0.1-0.15%
of patients among the general population during preventa-
tive therapy. Data on the tolerability of INH in hematologic
malignancy patients receiving concomitant chemotherapy is
limited.
Primary objective: To investigate the incidence of LTBI in
patients with hematologic malignancies at UC San Diego
Health System.
Secondary objective: To investigate the safety and tolera-
bility of INH for treatment of latent tuberculosis in patients
with hematologic malignancies receiving chemotherapy.
This is a prospective, single center study using data
collected from an electronic patient database. Recruitment is
still on-going; we hope to enroll a total of 100 patients in this
study. All patients presenting with hematologic malig-
nancies at the Moores Cancer Center are screened for LTBI asa part of the standard of care using the QuantiFERON-TB
Gold Test (QFT-IT). A value of 0.35 IU/mL QFT-IT result is
considered positive. Patients with values of 0.35-1 IU/mLwill
be retested in 3-6 months to conﬁrm positivity. If patients
consent to participate, data collection will begin and
continued for 9 months if treatment for LTBI is initiated.
Data collected: age, gender, race, place of birth, cancer
diagnosis, transplant type/conditioning regimen, medication
list, PPD result history, history of LTBI and past treatment,
QFT-IT result, baseline renal function, liver function tests at
baseline and throughout therapy if INH was initiated.
Treatment decisions in the cases of a positive QFT-IT is at the
discretion of the treating physician. A descriptive analysis
including means, medians, ranges and proportions will be
calculated.366
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Introduction: Clostridium difﬁcile infection (CDI) is
considered the most common cause of acute infectious
diarrhea among hospitalized patients and is a major
concern in the hematopoietic stem cell transplantation
(HSCT) setting. HSCT patients constitute a highly vulner-
able population for CDI. This susceptibility can be
attributed to long hospitalizations, prolonged exposure to
of broad-spectrum antibiotics and chemotherapy-related
disruption of enteric mucosal barriers. With the increase of
CDI prevalence over the last decade the morbidity,
mortality, and medical care costs of CDI have reached
historic highs; therefore there is a need for prevention
policies that apply to the speciﬁc characteristics of this
population. An infection prevention surveillance audit at
the South Texas Veterans Health Care System Bone Marrow
Transplant Unit, during a 3 month period (October-
December 2013), revealed an increase in the rate of
healthcare associated hospital onset (HAHO) CDI (>72
hours after admission).
Methods:We assembled a multidisciplinary team with the
aim to decrease the rate of CDI over a 3 months period
(January-March 2014). A team including physicians,
nurses, pharmacists and infection preventionist was
called in to evaluate the rates of CDI and establish pro-
cedures to decrease these rates. Interventions included
the following: education of staff and patients about CDI
prevention and transmission, hand hygiene awareness,
proper use of cleaning products, de-cluttering of nurses'
work station, decontamination of common areas, daily
chlorhexidine baths, revision and review of the daily
cleaning of rooms, environmental service supervisor
visual room inspection and feedback after terminal
cleaning, use of ultraviolet pulses of light (UVC pulsed
technology), restriction of CDI positive patients to their
room and contact precautions until 48 hours after
resolution of diarrhea stools.
Results: Visual inspection of the roomwas increased to 100%,
as rooms were not released until a sign was placed on the
door signed by the environmental service supervisor
performing the inspection. Usage of the UVC units increased
from 17.5 per month (pre-intervention) on average to 42 per
month (post intervention). Hand hygiene was 100% based on
